Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Pharmacological Reviews
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Pharmacological Reviews

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit Pharm Rev on Facebook
  • Follow Pharm Rev on Twitter
  • Follow ASPET on LinkedIn
OtherReview Article

Inhibitors of Brain Phospholipase A2 Activity: Their Neuropharmacological Effects and Therapeutic Importance for the Treatment of Neurologic Disorders

Akhlaq A. Farooqui, Wei-Yi Ong and Lloyd A. Horrocks
Pharmacological Reviews September 2006, 58 (3) 591-620; DOI: https://doi.org/10.1124/pr.58.3.7
Akhlaq A. Farooqui
Department of Molecular and Cellular Biochemistry, The Ohio State University, Columbus, Ohio (A.A.F., L.A.H.); and Department of Anatomy, National University of Singapore, Singapore, Singapore (W.-Y.O.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wei-Yi Ong
Department of Molecular and Cellular Biochemistry, The Ohio State University, Columbus, Ohio (A.A.F., L.A.H.); and Department of Anatomy, National University of Singapore, Singapore, Singapore (W.-Y.O.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lloyd A. Horrocks
Department of Molecular and Cellular Biochemistry, The Ohio State University, Columbus, Ohio (A.A.F., L.A.H.); and Department of Anatomy, National University of Singapore, Singapore, Singapore (W.-Y.O.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The phospholipase A2 family includes secretory phospholipase A2, cytosolic phospholipase A2, plasmalogen-selective phospholipase A2, and calcium-independent phospholipase A2. It is generally thought that the release of arachidonic acid by cytosolic phospholipase A2 is the rate-limiting step in the generation of eicosanoids and platelet activating factor. These lipid mediators play critical roles in the initiation and modulation of inflammation and oxidative stress. Neurological disorders, such as ischemia, spinal cord injury, Alzheimer's disease, multiple sclerosis, prion diseases, and epilepsy are characterized by inflammatory reactions, oxidative stress, altered phospholipid metabolism, accumulation of lipid peroxides, and increased phospholipase A2 activity. Increased activities of phospholipases A2 and generation of lipid mediators may be involved in oxidative stress and neuroinflammation associated with the above neurological disorders. Several phospholipase A2 inhibitors have been recently discovered and used for the treatment of ischemia and other neurological diseases in cell culture and animal models. At this time very little is known about in vivo neurochemical effects, mechanism of action, or toxicity of phospholipase A2 inhibitors in human or animal models of neurological disorders. In kainic acid-mediated neurotoxicity, the activities of phospholipase A2 isoforms and their immunoreactivities are markedly increased and phospholipase A2 inhibitors, quinacrine and chloroquine, arachidonyl trifluoromethyl ketone, bromoenol lactone, cytidine 5-diphosphoamines, and vitamin E, not only inhibit phospholipase A2 activity and immunoreactivity but also prevent neurodegeneration, suggesting that phospholipase A2 is involved in the neurodegenerative process. This also suggests that phospholipase A2 inhibitors can be used as neuroprotectants and anti-inflammatory agents against neurodegenerative processes in neurodegenerative diseases.

  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

PharmRev articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Pharmacological Reviews: 58 (3)
Pharmacological Reviews
Vol. 58, Issue 3
1 Sep 2006
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Pharmacological Reviews article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Inhibitors of Brain Phospholipase A2 Activity: Their Neuropharmacological Effects and Therapeutic Importance for the Treatment of Neurologic Disorders
(Your Name) has forwarded a page to you from Pharmacological Reviews
(Your Name) thought you would be interested in this article in Pharmacological Reviews.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherReview Article

Inhibitors of Brain Phospholipase A2 Activity: Their Neuropharmacological Effects and Therapeutic Importance for the Treatment of Neurologic Disorders

Akhlaq A. Farooqui, Wei-Yi Ong and Lloyd A. Horrocks
Pharmacological Reviews September 1, 2006, 58 (3) 591-620; DOI: https://doi.org/10.1124/pr.58.3.7

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
OtherReview Article

Inhibitors of Brain Phospholipase A2 Activity: Their Neuropharmacological Effects and Therapeutic Importance for the Treatment of Neurologic Disorders

Akhlaq A. Farooqui, Wei-Yi Ong and Lloyd A. Horrocks
Pharmacological Reviews September 1, 2006, 58 (3) 591-620; DOI: https://doi.org/10.1124/pr.58.3.7
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • I. Introduction
    • II. Multiplicity of Phospholipases A2 in Brain
    • III. Involvement of Phospholipase A2 Activity in Brain Injury
    • IV. Physiological and Pharmacological Effects of Phospholipase A2 Inhibitors
    • V. Phospholipase A2 Activity in Kainic Acid-Induced Neural Cell Injury
    • VI. Protection of Kainic Acid-Induced Neural Cell Injury by Phospholipase A2 Inhibitors
    • VII. Phospholipase A2 Activity in Neurological Disorders
    • VIII. Use of Phospholipase A2 Inhibitors for the Treatment of Neurological Disorders
    • IX. Prevention of Pain by Phospholipase A2 Inhibitors
    • X. Perspective and Direction for Future Studies
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • The Quest to Define and Target Cellular Senescence
  • Nanozymes for viral diagnosis and therapy
  • Structure and Inhibition of NLRP3 Inflammasome
Show more Review Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Pharmacological Reviews
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacology Research & Perspectives
ISSN 1521-0081 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics